El Corte Inglés steps up its cooperation with the Spanish Association Against Cancer (AECC) by allocating one million euros over the next five year...
These awards are organized by the Spanish Metastatic Breast Cancer Association to promote research in this area. The project presented by Dr. Alei...
On the occasion of World Cancer Day, to be held next Saturday, February 4, IDIBAPS, together with the AECC, has organized three meetings between vo...
The spin-off helmed by Aleix Prat received the award in the category of Collaborative Research in Transfer for Development for its HER2DX breast ca...
HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TIL...
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease an...
Aleix Prat is leading the research, which focuses on discovering new ways of diagnosing hormone receptor-positive breast cancer, as well as new the...
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
A study conducted at Hospital Clínic analysed the genetic profile of more than 300 patients with solid tumours using a liquid biopsy blood test, re...
